■为了更全面地了解卡博替尼与安慰剂在恶性肿瘤中的疗效和安全性,我们进行了系统评价和荟萃分析.这涉及分析一组已发表的随机对照试验以评估结果。
■我们使用RevMan5.3软件来评估收集的研究结果。我们关注的主要结果是无进展生存期(PFS),次要结局包括总生存期(OS)和疾病控制率(DCR).
■我们的研究结果表明,与安慰剂相比,卡博替尼显著延长患者的PFS[风险比(HR)0.37,95%置信区间(CI):0.32,0.43,p<0.00001].此外,卡博替尼改善了患者的OS[HR0.78,95CI:0.68,0.91,p=0.002]。虽然重要的是要注意,卡博替尼与引起消化的可能性更高有关,皮肤,和心血管相关不良事件[相对风险(RR)4.40,95%CI:3.10,6.25,p<0.00001]。
■根据我们的分析,卡博替尼显著延长恶性肿瘤患者的PFS和OS(p<0.01)。我们建议使用卡博替尼治疗晚期恶性肿瘤。然而,持续监测和管理与药物相关的不良事件非常重要.
■PROSPERO(编号:CRD42023449261)。
UNASSIGNED: To provide a more comprehensive understanding of the efficacy and safety profile of cabozantinib versus placebo in malignant tumors, we conducted a systematic
review and meta-analysis. This involved analyzing a collection of published randomized controlled trials to assess the outcomes.
UNASSIGNED: We used RevMan5.3 software to evaluate the outcomes of the collected studies. The primary outcome we focused on was progression-free survival (PFS), and the secondary outcomes included overall survival (OS) and disease control rate (DCR).
UNASSIGNED: Our findings revealed that compared to placebo, cabozantinib significantly extended the PFS of patients [hazard ratios (HR) 0.37, 95% confidence intervals (CI): 0.32, 0.43, p < 0.00001]. Additionally, cabozantinib improved the OS of patients [HR 0.78, 95%CI: 0.68, 0.91, p = 0.002]. While it is important to note that cabozantinib was associated with a higher likelihood of causing digestive, cutaneous, and cardiovascular related adverse events [relative risk (RR) 4.40, 95% CI: 3.10, 6.25, p < 0.00001].
UNASSIGNED: Based on our analysis, cabozantinib significantly prolonged the PFS and OS of patients with malignant tumors (p < 0.01). We recommend the use of cabozantinib in treating advanced malignant tumors. However, it is important to continuously monitor and manage the drug-related adverse events.
UNASSIGNED: PROSPERO (No. CRD42023449261).